Hologic has completed its acquisition of breast cancer surgery technologies developer Endomagnetics (Endomag) for approximately $310 million.
Hologic had announced signing the definitive agreement to purchase the Cambridge, U.K.-based Endomag in late April. Completion of the acquisition is subject to customary closing conditions, including regulatory approvals; further details of the transaction were not disclosed.
In a statement, Hologic affirmed that the transaction will add Endomag's wireless breast surgery localization and lymphatic tracing solutions to Hologic's breast surgery portfolio.
Endomag's products include the Magseed marker for magnetic tissue localization before surgery, the Magtrace lymphatic tracing injectable for breast cancer staging, and the Sentimag platform, which supports both localization and lymphatic tracing.
"We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio," Erik Anderson, president of Breast and Skeletal Health Solutions at Hologic, said.
"With our shared commitment to advancing women's health globally, we are excited to improve outcomes for patients and, together with our customers, redefine the standard of care for breast cancer intervention."
